Revance Therapeutics received a Complete Response Letter (CRL) from the FDA for its liquid botulinum toxin candidate, citing manufacturing and quality control deficiencies. The CRL does not reject the program outright but requires the company to resolve facility and process issues before resubmission—a timeline that typically adds 12 to 18 months to approval.
Regulatory
Revance Liquid Botox Hits Manufacturing Roadblock
FDA issues Complete Response Letter for liquid botulinum toxin over manufacturing compliance issues.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Manufacturing issues delay liquid toxin entry by 12–18 months.
This matters for practices watching the toxin pipeline. Revance's liquid formulation promised room-temperature stability and longer shelf life compared to powder reconstitution, potentially simplifying inventory management. The manufacturing setback delays that competitive advantage. For now, AbbVie's Botox, Galderma's Dysport, and Evolus's Jeuveau remain the only FDA-approved neuromodulators. Revance's delay extends the window before a fourth player enters the U.S. market—and keeps pricing pressure on existing players muted.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.